Active substance
Oxaprozin
- US FDA 16
- US price lines 1
- Safety 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OXAPROZIN | 600MG | tablet · oral | PANGEA | Prescription | 31 Jan 2001 |
| OXAPROZIN | 600MG | tablet · oral | DR REDDYS LABS LTD | Prescription | 31 Jan 2001 |
| OXAPROZIN | 600MG | tablet · oral | CHARTWELL | Prescription | 2 Sep 2004 |
| OXAPROZIN | 600MG | tablet · oral | AMNEAL PHARMS CO | Prescription | 4 May 2017 |
| COXANTO | 300MG | capsule · oral | SOLUBIOMIX | Prescription | 20 Oct 2023 |
| DAYPRO | 600MG | tablet · oral | PFIZER | Discontinued | 29 Oct 1992 |
| OXAPROZIN | 600MG | tablet · oral | WATSON LABS | Discontinued | 9 Feb 2001 |
| OXAPROZIN | 600MG | tablet · oral | MYLAN PHARMS INC | Discontinued | 28 Feb 2001 |
| OXAPROZIN | 600MG | tablet · oral | AARXION ANDA HLDING | Discontinued | 12 Apr 2001 |
| OXAPROZIN | 600MG | tablet · oral | SANDOZ | Discontinued | 27 Apr 2001 |
| OXAPROZIN | 600MG | tablet · oral | PHARMOBEDIENT | Discontinued | 17 Aug 2001 |
| OXAPROZIN | 600MG | tablet · oral | ACTAVIS ELIZABETH | Discontinued | 3 Oct 2001 |
| OXAPROZIN | 600MG | tablet · oral | SUN PHARM INDS INC | Discontinued | 3 Jan 2002 |
| OXAPROZIN | 600MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 13 May 2002 |
| OXAPROZIN | 600MG | tablet · oral | TEVA | Discontinued | 3 Jul 2002 |
| DAYPRO ALTA | 600MG | tablet · oral | PFIZER | Discontinued | 17 Oct 2002 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | OXAPROZIN 600 MG TABLET | $0.47536 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 DAYPRO — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 DAYPRO ALTA — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 COXANTO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.